GHRP-6

GHRP-6 – Growth Hormone-Releasing Peptide-6

Synthetic Hexapeptide for Ghrelin Receptor Signaling, Growth Hormone Secretion & Neuroendocrine Research

GHRP-6 (Growth Hormone-Releasing Peptide-6) is a synthetic hexapeptide investigated for its ability to stimulate endogenous growth hormone (GH) secretion through activation of the growth hormone secretagogue receptor type 1a (GHS-R1a).

GHRP-6 belongs to the growth hormone-releasing peptide family and represents one of the earliest synthetic compounds developed to investigate growth hormone secretagogue activity.

Unlike recombinant human growth hormone, GHRP-6 does not directly replace circulating GH. Instead, it interacts with receptor-mediated pathways that regulate hormone secretion.

GHRP-6 has been studied in experimental models involving pituitary hormone release, ghrelin receptor pharmacology, appetite regulation, hypothalamic signaling and the GH–IGF-1 axis.

Controlled human studies have demonstrated that GHRP-6 can stimulate acute GH secretion. Research has also documented effects on ACTH, cortisol, appetite-related pathways and selected sleep parameters.

However, increased GH secretion does not establish clinically meaningful improvements in muscle mass, fat loss, athletic performance, recovery or longevity.

ICAME Pharmacy GHRP-6 is intended strictly for laboratory research and development purposes. Not for human or veterinary use.

What Is GHRP-6?

GHRP-6 is a synthetic peptide consisting of six amino acid residues.

It was developed during early investigations into compounds capable of stimulating GH release independently of the classical growth hormone-releasing hormone receptor.

Its discovery contributed to the identification and characterization of the growth hormone secretagogue system.

GHRP-6 is relevant to research involving:

• Growth hormone secretion

• Ghrelin receptor activation

• Hypothalamic–pituitary physiology

• GH–IGF-1 signaling

• Appetite-associated pathways

• Neuroendocrine feedback

• ACTH and cortisol responses

• Sleep-associated endocrine regulation

• Peptide structure–activity relationships

• G protein-coupled receptor pharmacology

The compound is not a natural form of human growth hormone and should not be described as a clinically validated anabolic or anti-aging agent.

GHRP-6 Molecular Structure

GHRP-6 is a synthetic hexapeptide containing six amino acid residues, including D-amino acids.

Amino Acid Sequence

H-His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂

The sequence contains:

His — Histidine

D-Trp — D-Tryptophan

Ala — Alanine

Trp — Tryptophan

D-Phe — D-Phenylalanine

Lys — Lysine

The peptide has an amidated C-terminus.

Molecular Characteristics

Compound Name: Growth Hormone-Releasing Peptide-6

Abbreviation: GHRP-6

Alternative Research Identifier: SKF-110679

Peptide Classification: Synthetic Hexapeptide

Peptide Length: 6 Amino Acid Residues

Molecular Formula: C₄₆H₅₆N₁₂O₆

Approximate Molecular Weight: 873.0 g/mol

CAS Number: 87616-84-0

Primary Receptor: GHS-R1a

Principal Research Field: Growth Hormone Secretagogue Pharmacology

These molecular specifications describe the commonly referenced peptide structure.

A commercial preparation may contain a salt form or counterions that affect its complete analytical composition. Product-specific specifications should therefore be verified through the relevant Certificate of Analysis.

Discovery and Scientific Background

GHRP-6 emerged from research on synthetic peptides capable of stimulating GH secretion.

The discovery of growth hormone-releasing peptides was scientifically important because these compounds demonstrated that GH secretion could be stimulated through pathways distinct from those activated by endogenous GHRH.

Early investigations established that GHRP-6 could stimulate GH secretion in experimental animals and humans.

Subsequent research identified the growth hormone secretagogue receptor, providing a molecular explanation for the activity of this peptide family.

The discovery of ghrelin in 1999 further expanded understanding of the receptor's physiological role.

Ghrelin was identified as an endogenous ligand of GHS-R1a.

Although GHRP-6 and ghrelin differ substantially in molecular structure, both can activate the same receptor system.

This relationship established GHRP-6 as a valuable research tool in endocrine physiology and receptor pharmacology.

How Does GHRP-6 Work?

GHRP-6 primarily acts as an agonist of GHS-R1a, a G protein-coupled receptor associated with ghrelin signaling.

The receptor is expressed in several tissues, including structures involved in hypothalamic and pituitary regulation.

GHS-R1a activation can initiate intracellular signaling that promotes GH secretion.

Simplified Mechanism of Action

GHRP-6

↓

GHS-R1a Receptor Activation

↓

Gq/11-Associated Signaling

↓

Phospholipase C (PLC) Activation

↓

IP₃ / DAG Signaling

↓

Intracellular Calcium Mobilization

↓

Stimulation of Growth Hormone Secretion

↓

Investigation of GH–IGF-1 Axis Responses

This simplified pathway represents an established aspect of ghrelin receptor pharmacology.

Actual endocrine responses are influenced by receptor regulation, metabolic state, pituitary function and physiological feedback.

GHRP-6 and the Ghrelin Receptor

The growth hormone secretagogue receptor (GHS-R1a) is an important component of the endocrine and metabolic signaling network.

Its endogenous ligand, ghrelin, is a peptide hormone involved in growth hormone release and appetite-associated physiology.

GHRP-6 activates GHS-R1a despite lacking the same amino acid sequence as ghrelin.

Structural studies have demonstrated that GHRP-6 occupies the receptor's orthosteric binding region.

Its amino acid residues interact with specific receptor binding pockets, contributing to receptor activation.

These findings make GHRP-6 relevant to research involving:

Ligand–receptor recognition

Ghrelin receptor activation

GPCR structural biology

Receptor binding pockets

Intracellular signaling

Synthetic agonist design

GHRP-6 is particularly useful for studying how structurally different ligands can activate the same receptor.

GHRP-6 and Growth Hormone Secretion

Growth hormone is secreted by somatotroph cells in the anterior pituitary gland.

Its release is naturally pulsatile and influenced by several regulatory systems.

Important physiological regulators include:

Growth Hormone-Releasing Hormone (GHRH)

Somatostatin

Ghrelin

Sleep-Associated Signals

Nutritional Status

Metabolic Feedback

IGF-1-Associated Feedback

GHRP-6 stimulates GH secretion through the growth hormone secretagogue receptor pathway.

Human endocrine studies have documented increases in circulating GH following controlled experimental exposure.

These findings establish GHRP-6 as a biologically active growth hormone secretagogue.

However, acute GH stimulation should not be interpreted as evidence of sustained clinical benefit.

GHRP-6 and the GH–IGF-1 Axis

The growth hormone–insulin-like growth factor-1 (GH–IGF-1) axis plays an important role in growth, tissue metabolism and endocrine regulation.

Growth hormone acts on multiple tissues.

One of its important functions is stimulating IGF-1 production, particularly in the liver.

GH–IGF-1 Signaling Overview

Hypothalamic Regulation

↓

Anterior Pituitary GH Secretion

↓

GH Receptor Activation

↓

IGF-1-Associated Signaling

↓

Growth and Metabolic Regulation

GHRP-6 acts upstream by influencing GH secretion.

It is not equivalent to administering GH or IGF-1 directly.

Furthermore, the biological response to an acute GH secretagogue stimulus does not establish sustained increases in IGF-1 or improvements in health-related outcomes.

GHRP-6 and Hypothalamic–Pituitary Research

The hypothalamus and pituitary gland coordinate several important endocrine functions.

The hypothalamus produces regulatory signals that influence pituitary hormone secretion.

GHRP-6 has been investigated as a tool for studying this interaction.

Relevant research areas include:

• Somatotroph activity

• Hypothalamic signaling

• Pituitary responsiveness

• Hormonal feedback

• Growth hormone pulsatility

• Receptor-mediated secretion

• Neuroendocrine integration

GHRP-6 can stimulate GH secretion through mechanisms that differ from classical GHRH receptor activation.

This distinction has made it useful in comparative endocrine research.

GHRP-6 vs. Growth Hormone-Releasing Hormone

GHRH is an endogenous hypothalamic hormone that stimulates GH secretion.

It acts primarily through the GHRH receptor.

GHRP-6 activates the ghrelin receptor.

These receptors are associated with different intracellular signaling systems.

Experimental studies have examined the interaction between these pathways.

In certain research settings, combined receptor stimulation has produced GH responses greater than those observed with either stimulus alone.

These findings are relevant to endocrine physiology but do not establish the safety or efficacy of combining research compounds.

GHRP-6 and Appetite Regulation

One of the distinctive characteristics of the ghrelin signaling system is its relationship with appetite.

Ghrelin is often associated with hunger-related signaling and energy balance.

Because GHRP-6 activates GHS-R1a, researchers have investigated its effects on food intake and appetite-associated neural pathways.

Preclinical and human research supports the importance of this receptor system in feeding behavior.

GHRP-6 has been associated with orexigenic activity, meaning activity related to the stimulation of appetite.

Research areas include:

Hypothalamic feeding circuits

Appetite-associated signaling

Energy balance

Nutritional regulation

Ghrelin receptor pharmacology

Food intake behavior

These findings do not establish GHRP-6 as a clinically approved treatment for appetite loss or weight-related disorders.

GHRP-6 and Energy Balance Research

Energy balance depends on the relationship between energy intake and energy expenditure.

It is influenced by multiple hormonal and neural systems.

Ghrelin receptor signaling is associated with nutrient-related physiological responses.

GHRP-6 may therefore be relevant to research examining:

Energy intake

Appetite regulation

Neuroendocrine metabolism

GH-associated metabolic signaling

Nutritional state

Hormonal feedback

However, appetite stimulation and GH secretion may have different effects on overall energy balance.

It is scientifically inappropriate to conclude that GHRP-6 reliably promotes fat loss or improves body composition.

GHRP-6 and ACTH Research

Adrenocorticotropic hormone (ACTH) is produced by the anterior pituitary gland.

It plays an important role in the hypothalamic–pituitary–adrenal axis.

ACTH stimulates glucocorticoid production by the adrenal cortex.

Human studies have reported that GHRP-6 can stimulate ACTH secretion under certain experimental conditions.

This makes the compound relevant to research involving:

Pituitary hormone interactions

HPA axis physiology

Stress-associated endocrine signaling

ACTH secretion

Hormonal response testing

The magnitude of the response depends on the study population and experimental conditions.

GHRP-6 should not be described as selective exclusively for growth hormone secretion.

GHRP-6 and Cortisol Research

Cortisol is a glucocorticoid hormone involved in metabolism, stress responses and physiological regulation.

Controlled human studies have demonstrated that GHRP-6 can influence cortisol secretion.

In a 1995 sleep-endocrine study, GHRP-6 increased GH, ACTH and cortisol during the experimental observation period.

These findings demonstrate that GHRP-6 can influence multiple endocrine pathways.

Increased cortisol is not necessarily a desirable effect.

This broader hormonal activity is an important consideration when interpreting experimental results.

GHRP-6 and Prolactin Research

Prolactin is a pituitary hormone involved in reproductive and metabolic physiology.

Growth hormone secretagogues have been investigated for their potential effects on prolactin secretion.

Some experimental studies involving the GHRP family have reported prolactin responses.

However, the magnitude and consistency of these effects vary among compounds and experimental settings.

GHRP-6 may therefore be relevant to research involving pituitary hormone selectivity.

It should not be characterized as a completely GH-specific peptide.

GHRP-6 and Sleep Research

Growth hormone secretion is associated with sleep physiology.

A prominent GH secretory pulse often occurs during early nocturnal sleep.

Researchers have investigated whether synthetic GH secretagogues influence sleep-associated hormone patterns.

In a controlled human study published in 1995, GHRP-6 increased GH, ACTH and cortisol secretion.

The study also reported an increase in stage 2 sleep.

However, slow-wave sleep did not significantly change.

These findings demonstrate that GHRP-6 can influence certain sleep-associated physiological measurements.

They do not establish that GHRP-6 improves overall sleep quality or treats insomnia.

GHRP-6 and Sleep Architecture

Sleep architecture describes the organization of different sleep stages across the night.

It includes:

NREM Sleep

REM Sleep

Stage N2

Slow-Wave Sleep

Sleep Continuity

Sleep-Associated EEG Activity

GHRP-6 has been investigated in human sleep-endocrine experiments.

Results have varied according to experimental conditions.

A subsequent study examining different administration routes reported that endocrine and sleep-associated effects were not uniform across the investigated conditions.

These findings reinforce the importance of controlled study design.

GHRP-6 should not be presented as a proven sleep-promoting treatment.

GHRP-6 and Metabolic Research

Growth hormone influences multiple aspects of metabolism.

These include lipid metabolism, glucose regulation and tissue-associated signaling.

Because GHRP-6 stimulates GH secretion, it has attracted interest in metabolic research.

Relevant endpoints include:

• GH secretion

• IGF-1-associated responses

• Nutrient-related endocrine signaling

• Appetite regulation

• Glucose metabolism

• Lipid-associated pathways

• Hormonal feedback

However, the available clinical evidence does not establish GHRP-6 as an effective treatment for obesity, insulin resistance or other metabolic disorders.

GH-associated signaling may also influence glucose homeostasis in ways that require careful safety evaluation.

GHRP-6 and Skeletal Muscle Research

Skeletal muscle growth and maintenance depend on several interacting biological processes.

These include:

Mechanical loading

Protein synthesis and degradation

Nutritional status

Satellite cell activity

Hormonal regulation

Growth factor signaling

The GH–IGF-1 axis contributes to aspects of muscle physiology.

GHRP-6 has been discussed in relation to muscle biology because it stimulates endogenous GH secretion.

However, this does not establish that GHRP-6 increases muscle mass or strength in healthy humans.

Reliable conclusions about muscle growth require appropriately controlled studies measuring actual muscle and functional outcomes.

Hormone concentrations alone are insufficient.

GHRP-6 and Body Composition Research

Body composition includes lean tissue, adipose tissue and other body compartments.

Changes in body composition depend on many physiological and behavioral factors.

Because GHRP-6 influences GH and appetite-related pathways, it has been investigated in endocrine and metabolic research.

However, increased GH secretion should not be equated with fat reduction.

Likewise, appetite stimulation does not necessarily produce beneficial changes in body composition.

There is insufficient high-quality clinical evidence to establish GHRP-6 as an effective body-recomposition agent.

GHRP-6 and Aging-Related Endocrine Physiology

Growth hormone secretion changes throughout life.

Age-associated changes in GH pulsatility have been studied in relation to metabolism, sleep and body composition.

Growth hormone secretagogues have been investigated as tools for examining endocrine responsiveness across different populations.

GHRP-6 may therefore be relevant to research involving:

Age-associated GH secretion

Pituitary responsiveness

Endocrine feedback

Metabolic physiology

Hormonal rhythms

However, increasing GH secretion is not equivalent to reversing biological aging.

GHRP-6 has not been established as a safe or effective longevity treatment.

GHRP-6 and Receptor Structure Research

Structural biology has contributed significantly to understanding ghrelin receptor activation.

Research published in 2021 examined the molecular recognition of ghrelin and synthetic ligands, including GHRP-6.

The findings demonstrated how GHRP-6 interacts with the receptor's binding pocket.

Specific peptide residues contribute to receptor recognition and activation.

These observations are relevant to:

GPCR structure

Ligand binding

Receptor activation

Molecular pharmacology

Structure-guided ligand design

Peptide–receptor interactions

GHRP-6 is therefore an important research compound in receptor structural biology.

GHRP-6 and Peptide Structure–Activity Relationships

Structure–activity relationship research examines how molecular structure influences biological activity.

GHRP-6 contains D-amino acid residues that contribute to its synthetic peptide architecture.

These modifications distinguish it from many naturally occurring peptides.

Researchers have investigated how changes in peptide structure influence:

Receptor affinity

Biological activity

Peptide stability

Endocrine selectivity

Ligand recognition

Intracellular signaling

GHRP-6 has served as an important starting point for the development and investigation of other GH secretagogues.

GHRP-6 vs. GHRP-2

GHRP-6 and GHRP-2 belong to the same family of synthetic growth hormone-releasing peptides.

Both activate ghrelin receptor-associated signaling.

However, their molecular structures differ.

The magnitude of experimental effects depends on the study design.

Neither peptide should be marketed as a proven performance-enhancing or anti-aging treatment.

GHRP-6 vs. Ipamorelin

GHRP-6 and ipamorelin are synthetic growth hormone secretagogues.

Both have been investigated for their ability to activate GHS-R1a-associated pathways.

Ipamorelin was developed with an emphasis on selective GH-releasing activity in early experimental studies.

GHRP-6 has a longer research history and has demonstrated additional endocrine responses involving ACTH and cortisol.

These differences are relevant to experimental receptor pharmacology.

However, neither compound has established clinical efficacy for muscle growth, fat loss or longevity in healthy individuals.

GHRP-6 vs. Hexarelin

Hexarelin, also known as examorelin, is another synthetic growth hormone-releasing peptide.

It was developed through modifications of the GHRP family.

Both GHRP-6 and hexarelin have been investigated in endocrine research.

Relevant comparison areas include:

GH secretion

Receptor activity

Pituitary responsiveness

Hormonal selectivity

Structure–activity relationships

Experimental pharmacokinetics

Results from hexarelin studies should not automatically be attributed to GHRP-6.

The compounds have distinct molecular structures and pharmacological characteristics.

GHRP-6 vs. CJC-1295

GHRP-6 and CJC-1295 act through different receptor systems.

GHRP-6 activates the ghrelin receptor.

CJC-1295 is a modified analogue of GHRH that activates the GHRH receptor.

Experimental interaction between GHS-R1a and GHRH receptor signaling is scientifically relevant.

However, research findings do not establish the safety or efficacy of combined use.

Human Research on GHRP-6

GHRP-6 has been investigated in controlled human endocrine studies.

These studies provide evidence of acute biological activity.

Growth Hormone Secretion

Human investigations have demonstrated stimulation of circulating GH.

ACTH and Cortisol

Studies have reported changes in ACTH and cortisol secretion.

Sleep-Associated Endocrine Responses

A controlled study reported increased stage 2 sleep without a significant increase in slow-wave sleep.

Endocrine Responses in Different Physiological Conditions

Studies involving altered glucocorticoid status have shown that GH responses to GHRP-6 can differ across patient groups.

Important Limitation

These findings demonstrate experimental endocrine activity.

They do not establish GHRP-6 as an approved general-purpose treatment for muscle growth, body composition, aging or sleep disorders.

Potential Safety Concerns

GHRP-6 influences several interconnected endocrine pathways.

Important scientific considerations include:

Growth Hormone Regulation

Changes in GH signaling may affect multiple tissues and metabolic systems.

ACTH and Cortisol

Human studies have demonstrated stimulation of HPA-axis hormones.

Appetite Regulation

Ghrelin receptor activation can influence hunger and feeding behavior.

Glucose Homeostasis

GH-associated metabolic changes may influence insulin sensitivity and glucose regulation.

Prolactin-Associated Responses

Additional pituitary hormone responses require consideration.

Long-Term Safety

Repeated or prolonged exposure has not been adequately characterized for unapproved GHRP-6 preparations.

Product Quality

Research materials may differ in identity, purity, salt form and analytical specifications.

No research-grade peptide should be assumed suitable for human administration.

GHRP-6 and Anti-Doping Regulations

GHRP-6 is included among prohibited growth hormone-releasing peptides under the World Anti-Doping Agency (WADA) framework.

It is classified within the prohibited category covering peptide hormones, growth factors and related substances.

GHRP-6 is prohibited in sport both in and out of competition.

Its availability as a laboratory research compound does not exempt it from anti-doping restrictions.

Researchers and distributors should also consider applicable national regulations governing peptide substances.

Scientific Evidence and Research Limitations

GHRP-6 has a well-established history in experimental endocrine pharmacology.

However, scientific evidence differs substantially across proposed applications.

Established Research Findings

• GHRP-6 is a synthetic hexapeptide.

• It activates GHS-R1a-associated signaling.

• It stimulates acute GH secretion in humans.

• It has been investigated in appetite-associated research.

• Human studies have documented ACTH and cortisol responses.

• It has been studied in sleep-endocrine experiments.

• Structural research has characterized its interactions with the ghrelin receptor.

Important Limitations

• Long-term safety is not adequately established.

• Clinical efficacy for muscle hypertrophy is unproven.

• Clinical efficacy for fat loss is unproven.

• Anti-aging and longevity claims are unsupported.

• GH secretion does not guarantee improved body composition.

• Endocrine effects vary across experimental conditions.

• Research-grade products are not equivalent to authorized pharmaceuticals.

• Unsupervised human use may involve substantial endocrine and product-quality risks.

These limitations should be clearly communicated in scientific product descriptions.

Potential Research Applications

GHRP-6 may be relevant to appropriately controlled scientific investigations involving:

• Growth hormone secretion

• Ghrelin receptor pharmacology

• GHS-R1a activation

• Hypothalamic–pituitary physiology

• GH–IGF-1 axis research

• G protein-coupled receptor signaling

• Phospholipase C pathways

• Intracellular calcium signaling

• Pituitary somatotroph function

• ACTH and cortisol responses

• Appetite-associated neural pathways

• Energy balance

• Sleep-endocrine interactions

• Neuroendocrine feedback

• Receptor structural biology

• Peptide structure–activity relationships

• Synthetic peptide chemistry

• Endocrine pharmacology

• Growth hormone secretagogue selectivity

These are scientific research areas, not established therapeutic benefits.

GHRP-6 Research Overview

Compound Name: Growth Hormone-Releasing Peptide-6

Abbreviation: GHRP-6

Alternative Identifier: SKF-110679

Classification: Synthetic Growth Hormone Secretagogue

Peptide Length: 6 Amino Acid Residues

Sequence: H-His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂

Molecular Formula: C₄₆H₅₆N₁₂O₆

Approximate Molecular Weight: 873.0 g/mol

CAS Number: 87616-84-0

Primary Receptor: GHS-R1a

Principal Research Pathway: Ghrelin Receptor Signaling

Primary Experimental Effect: Stimulation of GH Secretion

Additional Research Areas: Appetite / ACTH / Cortisol / Sleep-Endocrine Physiology

Clinical Performance Benefits: Not established

Anti-Doping Status: Prohibited under WADA rules

Product Information

Product Name: GHRP-6

Full Name: Growth Hormone-Releasing Peptide-6

Brand: ICAME Pharmacy

Product Category: Research Peptide

Research Classification: Synthetic Growth Hormone Secretagogue

Research Areas: GH Secretion / Ghrelin Receptor Signaling / Neuroendocrine Physiology

Intended Use: Laboratory Research & Development Only

The exact identity and specifications of the supplied material should be confirmed through manufacturer documentation.

Relevant batch-specific information includes:

• Verified amino acid sequence

• Chemical form and counterion

• Molecular identity

• Analytical purity

• Peptide content

• Certificate of Analysis (COA)

• Batch/lot identification

• Validated storage conditions

No claims of pharmaceutical quality, sterility, human suitability or therapeutic efficacy should be made without appropriate supporting documentation and regulatory authorization.

Important Research Use Notice

FOR RESEARCH USE ONLY (RUO)

This ICAME Pharmacy product is intended exclusively for legitimate laboratory, analytical and scientific research purposes.

Not for human or veterinary use. Not for diagnostic, therapeutic, muscle-building, weight-loss, performance-enhancing, anti-aging or other clinical purposes. Not for direct administration to humans or animals.

GHRP-6 is a biologically active growth hormone secretagogue.

Human studies demonstrate acute endocrine activity, including GH secretion and possible ACTH, cortisol and other hormonal responses.

However, long-term safety and clinical efficacy for performance, body composition and aging-related outcomes have not been established.

GHRP-6 is prohibited in sport under anti-doping regulations.

Information presented on this page is intended solely for scientific and educational purposes and does not constitute medical advice, prescribing information, dosage guidance or instructions for human use.

About ICAME Pharmacy

ICAME Pharmacy provides specialized research products for professional laboratory and scientific applications.

Our portfolio focuses on compounds relevant to peptide science, endocrinology, molecular biology, receptor signaling, experimental pharmacology and life sciences research.

We emphasize accurate product identification, responsible research use, scientific transparency and clear communication of evidence limitations.

For batch-specific analytical documentation and product inquiries, please contact ICAME Pharmacy.